1. Home
  2. NPV vs CHRS Comparison

NPV vs CHRS Comparison

Compare NPV & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Virginia Quality Municipal Income Fund

NPV

Nuveen Virginia Quality Municipal Income Fund

BUY

Current Price

$9.40

Market Cap

184.3M

Sector

Finance

ML Signal

BUY

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

BUY

Current Price

$1.07

Market Cap

177.7M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
NPV
CHRS
Founded
1993
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
184.3M
177.7M
IPO Year
1995
2014

Fundamental Metrics

Financial Performance
Metric
NPV
CHRS
Price
$9.40
$1.07
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
★ $7.75
AVG Volume (30 Days)
122.1K
★ 1.4M
Earning Date
01-01-0001
11-05-2026
Dividend Yield
★ 3.90%
N/A
EPS Growth
N/A
★ 472.00
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$44.19
Revenue Next Year
N/A
$65.06
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$9.05
$1.01
52 Week High
$11.81
$2.62

Technical Indicators

Market Signals
Indicator
NPV
CHRS
Relative Strength Index (RSI) 34.43 34.34
Support Level $9.05 N/A
Resistance Level $11.61 $1.53
Average True Range (ATR) 0.18 0.09
MACD 0.02 -0.02
Stochastic Oscillator 41.60 13.38

Price Performance

Historical Comparison
NPV
CHRS

About NPV Nuveen Virginia Quality Municipal Income Fund

Nuveen Virginia Quality Municipal Income Fund is a diversified closed-end management investment company. The fund seeks to provide current income exempt from both regular federal and designated state income taxes. The fund invests in a portfolio of municipal obligations issued by state and local government authorities. The company mostly invests in Education and Civic Organizations, Tax Obligation/General, Healthcare, Utilities, Housing/Multifamily, Transportation, and Others.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

Share on Social Networks: